Trump’s new tariffs on China are important for strengthening US medical security and supply chain elasticity. Some medical institutions expressed concern, but these new measures and additional target tariffs are not only essential to protecting our national interests and ensuring stable supply of important medical products.
Public opinion is behind the president’s actions. According to a recent 12 polls of the New York Times, a poll found that the polls tend to be equally divided into new tariffs. But when ordering China, support for tariffs changes significantly.
Customs will reduce the vulnerability of foreign interruption by encouraging companies to invest in US -based production. The United States, which has faced disasters and health emergencies for the past decade, has seriously lacked serious medical supplies due to over -medical sources for imports of China. By fostering domestic manufacturing, we can use important medical products when we need it most.
Since March 4, the economic stadium has not been selected. The president has announced a new 10%tariff on all Chinese products. Chinese medical gloves combined with existing tariffs are taxed at 70%, with 45%of new rates, masks and respiratory systems and 120%. This tariff began to reverse the years of exploitation practices by bad actors.
Critics argue that the global supply chain provides duplicate, but the United States’ excessive dependence on foreign sources exposes it to designated scientific tensions and trade restrictions. For example, most of the test gloves used in the United States are from Asia or are routed through third -party non -democratic countries. If domestic manufacturing is built, reliable standards are guaranteed to provide confidence in the stability of the medical supply chain.
This strategic change improves national security, promotes the domestic economy, and creates jobs.
Some claim tariffs affect medical costs, but long -term benefits are more important than short -term adjustments. Domestic production can stabilize prices and reduce federal medical program costs such as Veterans, Medicare, and Medicaid, and potentially lower them.
Policy drafts should focus on providing tax incentives and medicare payment adjustments to companies that want to invest and manufacture US -based production facilities.
The medical supply chain is too important to leave at the mercy of a foreign supplier that prioritizes the priority may not match us. Target tariffs are a key element of a greater strategy to reduce the dependence on imports and allow US medical service providers to trust them with important suppliers.
This strategy will lead to innovation and significant job creation and promote a better medical system that can face future challenges. Domestic producers of important medical goods are ready to compete with global competition, which is a fair fight.
Eric AXEL is the executive director of the American Medical Manufacturers Association./Insidesources
